Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard L Wasserman

Showing results (71-80 of 98) with videos related to

Pageof 10
Sort By:
The Journal of Allergy and Clinical Immunology|August 1, 2012
Recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulins for primary immunodeficiencyRichard L Wasserman, Isaac Melamed, Mark R Stein, et al.
Journal of Clinical Immunology|March 23, 2011
Efficacy, safety, and pharmacokinetics of a 10% liquid immune globulin preparation (GAMMAGARD LIQUID, 10%) administered subcutaneously in subjects with primary immunodeficiency diseaseRichard L Wasserman, Isaac Melamed, Lisa Kobrynski, et al.
Journal of Clinical Immunology|March 14, 2025
Efficacy, Safety, Tolerability, and Serum IgG Trough Levels of Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 10% in US Pediatric Patients with Primary Immunodeficiency DiseasesNiraj C Patel, Jolan E Walter, Richard L Wasserman, et al.
Allergy and Asthma Proceedings|August 4, 2012
Treatment response after repeated administration of C1 esterase inhibitor for successive acute hereditary angioedema attacksTimothy J Craig, Againdra K Bewtra, David Hurewitz, et al.
Journal of Clinical Immunology|March 7, 2012
Safety, efficacy and pharmacokinetics of a new 10% liquid intravenous immunoglobulin (IVIG) in patients with primary immunodeficiencyRichard L Wasserman, Joseph A Church, Mark Stein, et al.
Advances in Therapy|May 9, 2026
Clinical Evaluation of Pharmacokinetics, Efficacy, and Safety of a 10% Immunoglobulin in Primary Immunodeficiency Disease (CARES10 Study)Chaim M Roifman, Donald McNeil, William Lumry, et al.
Clinical Immunology (Orlando, Fla.)|November 17, 2009
Use of intravenous immunoglobulin and adjunctive therapies in the treatment of primary immunodeficiencies: A working group report of and study by the Primary Immunodeficiency Committee of the American Academy of Allergy Asthma and ImmunologyPierre L Yong, John Boyle, Mark Ballow, et al.
The Journal of Allergy and Clinical Immunology. in Practice|March 16, 2024
Age-Related Food Aversion and Anxiety Represent Primary Patient Barriers to Food Oral ImmunotherapyJordan Trevisonno, Carina Venter, Kaci Pickett-Nairne, et al.
The Journal of Allergy and Clinical Immunology|September 22, 2009
Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacksTimothy J Craig, Robyn J Levy, Richard L Wasserman, et al.
Journal of Clinical Immunology|May 18, 2006
Efficacy, safety and tolerability of a new 10% liquid intravenous immune globulin [IGIV 10%] in patients with primary immunodeficiencyJoseph A Church, Heinz Leibl, Mark R Stein, et al.
Pageof 10

Showing results (71-80 of 98) with videos related to

Sort By:
Pageof 10
The Journal of Allergy and Clinical Immunology|August 1, 2012
Recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulins for primary immunodeficiencyRichard L Wasserman, Isaac Melamed, Mark R Stein, et al.
Journal of Clinical Immunology|March 23, 2011
Efficacy, safety, and pharmacokinetics of a 10% liquid immune globulin preparation (GAMMAGARD LIQUID, 10%) administered subcutaneously in subjects with primary immunodeficiency diseaseRichard L Wasserman, Isaac Melamed, Lisa Kobrynski, et al.
Journal of Clinical Immunology|March 14, 2025
Efficacy, Safety, Tolerability, and Serum IgG Trough Levels of Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 10% in US Pediatric Patients with Primary Immunodeficiency DiseasesNiraj C Patel, Jolan E Walter, Richard L Wasserman, et al.
Allergy and Asthma Proceedings|August 4, 2012
Treatment response after repeated administration of C1 esterase inhibitor for successive acute hereditary angioedema attacksTimothy J Craig, Againdra K Bewtra, David Hurewitz, et al.
Journal of Clinical Immunology|March 7, 2012
Safety, efficacy and pharmacokinetics of a new 10% liquid intravenous immunoglobulin (IVIG) in patients with primary immunodeficiencyRichard L Wasserman, Joseph A Church, Mark Stein, et al.
Advances in Therapy|May 9, 2026
Clinical Evaluation of Pharmacokinetics, Efficacy, and Safety of a 10% Immunoglobulin in Primary Immunodeficiency Disease (CARES10 Study)Chaim M Roifman, Donald McNeil, William Lumry, et al.
Clinical Immunology (Orlando, Fla.)|November 17, 2009
Use of intravenous immunoglobulin and adjunctive therapies in the treatment of primary immunodeficiencies: A working group report of and study by the Primary Immunodeficiency Committee of the American Academy of Allergy Asthma and ImmunologyPierre L Yong, John Boyle, Mark Ballow, et al.
The Journal of Allergy and Clinical Immunology. in Practice|March 16, 2024
Age-Related Food Aversion and Anxiety Represent Primary Patient Barriers to Food Oral ImmunotherapyJordan Trevisonno, Carina Venter, Kaci Pickett-Nairne, et al.
The Journal of Allergy and Clinical Immunology|September 22, 2009
Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacksTimothy J Craig, Robyn J Levy, Richard L Wasserman, et al.
Journal of Clinical Immunology|May 18, 2006
Efficacy, safety and tolerability of a new 10% liquid intravenous immune globulin [IGIV 10%] in patients with primary immunodeficiencyJoseph A Church, Heinz Leibl, Mark R Stein, et al.
Pageof 10